ribosomal protein L21 pseudogene 12Genealiases: []
Q-omics provides the consensus-scored RPL21P12 profile across patient tissues and cancer cell-line models. RPL21P12 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RPL21P12 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, RPL21P12 RNA expression shows 6,684 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, COAD, and STAD as cancer lineages where RPL21P12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL21P12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL21P12 survival associations across molecular data types. RPL21P12 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL21P12 RNA expression–survival associations across cancer types. High RPL21P12 expression shows unfavorable associations in KICH, KIRC, ACC and PAAD, but favorable associations in BLCA and LUSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KICH as the clearest survival context for RPL21P12 RNA expression.
This table summarizes RPL21P12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL21P12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL21P12 shows lower tumor expression in BRCA and THCA and higher tumor expression in COAD and BLCA. The COAD box plot shows higher RPL21P12 RNA expression in tumor versus normal tissue (log2 FC = +0.226, t-test p = .001).
This table shows molecular features associated with RPL21P12 in patient tissues and cancer cell lines. In patient samples, RPL21P12 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
